Where does Stoke Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$6.89M+92.3%	-$88.98M+15.0%	-$104.7M-3.6%	-$101.07M-17.8%
Depreciation and amortization	$1.77M-18.7%	$2.18M-11.8%	$2.47M+59.7%	$1.55M+58.7%
Stock-based compensation	$32.24M+17.4%	$27.47M+8.8%	$25.26M+10.5%	$22.85M+38.9%
Change in accounts receivable	——	$50K—	——	——
Change in other assets	——	——	-$529K—	——
Change in deferred revenue	——	-$29.39M—	——	——
Net cash from operating activities	——	-$86.85M-7.1%	-$81.07M-154%	-$31.87M+52.4%
Capital expenditures	$670K+230%	$203K-87.4%	$1.62M-59.2%	$3.96M+230%
Net cash from investing activities	-$195.91M-80.9%	-$108.29M-202%	$105.95M—	——
Proceeds from issuance of common stock	$8.6M+400%	$1.72M+358%	$376K-23.9%	$494K-36.4%
Net cash from financing activities	$97.39M-25.7%	$131.09M+147%	$53.01M+14.2%	$46.41M+3,514%
Net increase (decrease) in cash	-$44.66M+29.4%	-$63.23M-179%	$79.97M—	——
Depreciation	$1.77M-18.7%	$2.18M-11.8%	$2.47M+59.7%	$1.55M+58.7%
Increase Decrease In Accounts Payable Accrued Liabilities And Opertaing Leases	$21.29M—	——	——	-$3.53M—
Deferred revenue	——	-$29.39M—	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	-$529K—	——
Reduction In Carrying Amount Of Operating Lease Right Of Use Assets	$2.41M+6.3%	$2.27M+0.2%	$2.26M+13.6%	$1.99M+58.4%
Proceeds From Controlled Equity Offering Sales Agreement Net Of Commissions	$87.78M+880%	$8.96M-82.8%	$52.08M—	——
Proceeds From Issuance Of Common Stock In Controlled Equity Offering Sales Agreement	——	——	——	——
Proceeds from issuance of common stock relating to employee stock plans	——	——	$555K—	——
Accrued payables for capital expenditures	$482K+690%	$61K—	——	——
Free cash flow	——	-$87.05M-5.3%	-$82.68M-131%	-$35.83M+47.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Stoke Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.